Competitive Advantages:
Prevents restenosis, Reduces inflammation, Reduces hypercoagulability, Preserves endothelial cell function.
The present invention provides for the incorporation of target sequences of microRNAs into the 3'UTR region of a gene of interest in nucleic acid vectors. The invention also provides for an expression system comprising such vectors, a pharmaceutical composition comprising such vectors, as well as methods of treating or preventing cardiovascular disease by using such vectors.USF researchers have developed the first miRNA-based strategy to selectively inhibit VSMC proliferation and migration for the prevention of restenosis, without concurrently inhibiting reendothelialization and EC function. This was achieved by the design of a novel vector that inhibits VSMCs and selectively preserving ECs. This vector was shown to reduce hypercoagulation and restore EC function in vivo. The combination of a better stent platform and biodegradable polymer with this novel strategy, has the potential to revolutionize the future of vascular interventional medicine.
Brochure
